Tesofensine: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •8 known side effects documented
- •4 mild, 4 moderate, 0 severe
- •9 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Most frequent adverse event in the Astrup 2008 Phase 2 trial; reported across all active doses and dose-dependent. Consistent with central and peripheral noradrenergic effects.
Dose-dependent insomnia and disturbed sleep, attributed to monoamine reuptake inhibition (noradrenergic and dopaminergic activation). Reported in the Astrup 2008 trial and consistent with the pharmacological class.
Reported in the Astrup 2008 Phase 2 trial across all active doses; generally mild-to-moderate and self-limited.
Reported in the Astrup 2008 trial; consistent with serotonergic and anticholinergic-like effects.
Mean increases of approximately 7-8 bpm in the higher-dose Phase 2 groups (Astrup 2008). The principal safety signal motivating the development of the combination product Tesomet (with metoprolol).
Modest increases in systolic and diastolic blood pressure reported, consistent with sympathomimetic activity.
Mood-related effects reported, particularly in earlier Parkinson's and Alzheimer's trials. Mechanism consistent with central monoamine modulation.
Reported across studies of tesofensine; mechanism likely related to sympathomimetic activity.
Side effects frequency chart for Tesofensine
Infographic pending generation
⛔Contraindications
- •Concurrent use of monoamine oxidase inhibitors (MAOIs) - serotonin syndrome risk
- •Concurrent use of other serotonergic agents (SSRIs, SNRIs, triptans, tramadol) without medical supervision - serotonin syndrome risk
- •Uncontrolled hypertension
- •Recent (less than 6 months) myocardial infarction or unstable angina
- •Significant cardiac arrhythmias
- •History of substance use disorder involving stimulants
- •Severe psychiatric illness, including bipolar disorder and psychotic disorders
- •Pregnancy and lactation (insufficient human data)
- •Closed-angle glaucoma (theoretical, based on noradrenergic activity)
Side effect frequency visualization for Tesofensine
Infographic pending generation
⚠️Drug Interactions
- •MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline) - serotonin syndrome risk; absolute contraindication
- •SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, duloxetine) - serotonin syndrome risk; avoid combination
- •Triptans (sumatriptan, rizatriptan) - additive serotonergic risk
- •Tramadol and meperidine - serotonin syndrome risk
- •Sympathomimetics (pseudoephedrine, amphetamines) - additive cardiovascular effects
- •CYP3A4 and CYP2D6 inhibitors / inducers - potential alteration of tesofensine plasma levels
- •Other dopaminergic agents (bupropion, methylphenidate, levodopa) - additive dopaminergic effects, theoretical psychiatric risk
Tesofensine Side Effects and Safety Profile#
Reported Side Effects#
The side-effect profile of tesofensine is characteristic of a triple monoamine reuptake inhibitor (SNDRI) with notable noradrenergic activity. In the 24-week Phase 2 obesity trial (Astrup et al., Lancet 2008; PMID 18950853)1, the most frequently reported adverse events were:
- Dry mouth - very common, dose-dependent
- Nausea - common, generally mild
- Constipation and hard stools - common
- Diarrhoea - reported
- Insomnia - common, dose-dependent; consistent with noradrenergic and dopaminergic activation
- Headache - common
- Heart-rate increase - mean approximately 7-8 bpm at higher doses (0.5 mg and 1.0 mg)
- Blood-pressure increase - small but measurable; principal cardiovascular safety signal
The heart-rate signal is the single most important driver of the Tesomet combination strategy: Saniona's Tesomet product pairs tesofensine with the cardioselective beta-1 blocker metoprolol specifically to blunt this effect2.
Less Common but Clinically Important Effects#
- Mood changes (irritability, anxiety, dysphoria) - reported particularly in the earlier Parkinson's and Alzheimer's trials
- Sleep architecture changes - beyond simple insomnia
- Sympathomimetic effects - palpitations, tremor
Comparison With Peptide GLP-1 Agonists#
| Effect class | Tesofensine | Semaglutide | Tirzepatide |
|---|---|---|---|
| GI (nausea, vomiting, diarrhoea) | Mild-moderate | Very common, often dominant | Very common |
| Sympathomimetic (heart rate, BP) | Common (dose-dependent) | Modest heart-rate increase (3-4 bpm) | Modest heart-rate increase |
| CNS (insomnia, mood, irritability) | Common | Rare | Rare |
| Pancreatitis / gallbladder | Not reported | Rare but real | Rare but real |
| Hypoglycaemia (in non-diabetic) | Not expected | Rare | Rare |
Contraindications#
Based on the pharmacology of triple monoamine reuptake inhibition:
- MAOIs - serotonin syndrome risk; absolute contraindication
- Other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, meperidine) - additive risk
- Uncontrolled hypertension or significant cardiovascular disease
- Recent (less than 6 months) MI or unstable angina
- Significant cardiac arrhythmias
- Severe psychiatric illness (bipolar disorder, psychotic disorders)
- History of stimulant use disorder
- Pregnancy and lactation - insufficient human data
- Closed-angle glaucoma - theoretical, based on noradrenergic activity
Drug Interactions#
Tesofensine's monoamine reuptake inhibition makes it pharmacologically interactive with a wide range of psychiatric, pain, and stimulant medications:
- MAOIs: Absolute contraindication; serotonin-syndrome risk
- SSRIs / SNRIs: Avoid combination without specialist input
- Triptans, tramadol, meperidine: Serotonin-syndrome risk
- Sympathomimetics (pseudoephedrine, amphetamines): Additive cardiovascular load
- CYP3A4 / CYP2D6 inhibitors and inducers: Potential effect on tesofensine plasma levels
- Other dopaminergic agents (bupropion, methylphenidate, levodopa): Additive dopaminergic effects with theoretical psychiatric risk
Because of tesofensine's terminal half-life of approximately 220 hours3, interaction risk persists for weeks after discontinuation.
Important Safety Notice#
- Tesofensine is investigational and not approved for marketing in the US, EU, or other major jurisdictions as of June 2026
- The side-effect profile above is summarized from clinical-trial settings with monitoring; real-world use without monitoring could plausibly produce more severe outcomes
- Mood, sleep, cardiovascular, and drug-interaction monitoring is appropriate during any clinical use
- This page does not constitute medical advice
References#
Related Reading#
- Tesofensine overview
- Tesofensine research studies
- Tesofensine risks and legal status
- Semaglutide side effects
Footnotes#
-
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9653):1906-1913. PMID: 18950853. DOI: 10.1016/S0140-6736(08)61525-1. ↩
-
Saniona AB. Tesofensine / Tesomet pipeline. https://saniona.com/pipeline/tesofensine. Accessed June 2026. ↩
-
Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs. 2009;10(10):1105-1116. PMID: 19777399. ↩
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Tesofensine
What are the most common Tesofensine side effects?
In the Astrup 2008 Phase 2 trial (PMID 18950853), the most common side effects were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia. Heart-rate increases of approximately 7-8 bpm were also documented at the higher 0.5 mg and 1.0 mg doses.
Why does Tesofensine raise heart rate?
Tesofensine inhibits reuptake of noradrenaline (norepinephrine), increasing sympathetic nervous system tone. This produces small but consistent increases in heart rate (mean approximately 7-8 bpm at higher doses in Phase 2) and modest blood-pressure increases. This is the principal safety concern motivating the Tesomet combination with metoprolol.
Can Tesofensine cause serotonin syndrome?
Yes - because tesofensine increases synaptic serotonin (via SERT inhibition), combining it with other serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans, tramadol) carries a serotonin-syndrome risk. MAOIs are contraindicated; SSRIs and SNRIs should not be combined without medical supervision.
Does Tesofensine have abuse potential?
Tesofensine inhibits the dopamine transporter (DAT), and DAT-active drugs generally carry stimulant-class abuse-liability concerns. However, tesofensine's slow onset and very long half-life make it pharmacokinetically dissimilar to high-abuse-liability stimulants such as cocaine or methamphetamine. Abuse-liability signals have not emerged as a primary concern in published clinical trials to date, but real- world post-marketing data are not yet available.
How does the Tesofensine side-effect profile compare with Semaglutide?
The two drug classes have largely non-overlapping side-effect profiles. Semaglutide and other GLP-1 agonists are dominated by gastrointestinal adverse events (nausea, vomiting, diarrhoea) and rare pancreatitis / gallbladder events. Tesofensine has milder GI signal and more prominent sympathomimetic effects (heart rate, blood pressure, dry mouth, insomnia) and CNS effects (mood, sleep).
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.